Building a Biotech Basket

 | Jun 11, 2014 | 5:00 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

kerx

,

aveo

,

kin

,

idix

Tuesday, I wrote about value investor Seth Klarman's multi-year foray into the land of biotech stocks and why such a highly regarded value investor would venture into stocks that are widely considered speculative. Most biotechs generate no profits, employ a lot of leverage or issue equity to fund drugs that often never realize any commercial value. But for those biotechs that do succeed, the payoff is many fold. Look at Klarman's recent experience with Idenix Pharmaceuticals (IDIX). Shortly after Klarman's Baupost Group took a 30% stake in the company, Merck (MRK) made an offer to buy it at a 230% premium.

Over the past several years, Klarman has taken many small stakes in various biotechs. Why not copy the master and create your own basket of biotechs? Instead of betting a lot on one, bet a little on several. A single winner will more than make up for a few duds. And if you select carefully, odds are even better that the basket will produce more than one winner and very few losers.

Let's start with the obvious picks, the ones that Klarman still owns today that have not spiked up on a buyout or other milestones. Keryx Biopharmaceuticals (KERX) is a new position initiated by Baupost during the most-recent quarter. Shares trade for about $14, up from a 52-week low of $6, valuing the company at $1.3 billion. Keryx focuses on drugs that treat renal disease.

AVEO Pharmaceuticals (AVEO) is micro-cap biotech focusing on cancer drugs. The company has a market cap of $65 million and Baupost has an approximately 8% stake. AVEO currently has two compounds in Phase 1 and Phase 2 studies.

Kindred Biosciences (KIN) is a name I have written about several times and probably the most intriguing idea. It focuses on drugs for pets -- namely cats and dogs. Shares have been quite volatile. When I first mentioned the company, shares were trading in the mid-teens and went as high as $23 before coming back to $15. Currently, shares trade around $19, valuing the company at approximately $370 million.

Our little biotech basket will consist of these three names for now. While there are dozens of biotech companies, I want to limit the basket to names that have been either screened by other investors or have candidates that are in latter stages of the trial cycle. Those that make the cut will be added, and I hope to have five to seven names in the basket. Each month I will track the performance of this basket and see how it stands up against other biotech exchange-traded funds.

Columnist Conversations

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market gets hit from impact of sanctions against Russia for second day in row but manages to rally a bit to en...
We took out some of the high end of support, but I'm still looking at this symmetrical pullback for entries on...
going into trading today roughly 37 million shares of X (US Steel) was held short.today big X has traded 27 mi...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.